Statement of Principles concerning dengue virus infection (Balance of Probabilities) (No. 79 of 2020)

The Statement organises its mechanics around a small set of core concepts: dengue virus infection (definition and clinical scope), exposure, time window, inability to obtain appropriate clinical management, relevant service, and relationship to other Statements of Principles. Each concept is defined or bounded in the instrument, and those definitions determine how claims are assessed.

Dengue virus infection. The instrument defines the disease as “an illness caused by infection with dengue virus” (s 7(2)). The instrument includes clinical descriptors for uncomplicated illness (fever, headache, eye pain, myalgia, arthralgia, nausea, vomiting, rash) and for complicated presentations (dengue with warning signs, severe dengue, dengue haemorrhagic fever, dengue shock syndrome) with manifestations such as thrombocytopenia, severe bleeding, plasma leakage, fluid accumulation, shock, impaired consciousness and organ failure (s 7(2), notes). The instrument notes that dengue attracts ICD‑10‑AM codes A90 or A91 but expressly states that the operative meaning in the instrument is the definition in s 7(2) regardless of code (s 7(3)-(4)).

Exposure. The Schedule 1 dictionary defines “being exposed to dengue virus” in four alternative ways: (a) being bitten by a mosquito infected with dengue virus; (b) being in a country or area when there is dengue virus transmission; (c) percutaneous or mucocutaneous exposure to blood infected with dengue virus; or (d) receiving blood, blood products, stem cell or organ transplants infected with dengue virus (Schedule 1 - Dictionary, definition of being exposed to dengue virus). These alternative modes broaden the recognised mechanisms of acquisition beyond classic mosquito bite exposure.

Temporal window. Section 9(1) imposes a precise temporal threshold: exposure must have occurred within 14 days before the clinical onset of dengue virus infection. The instrument therefore ties causation to a narrow pre‑onset period.

Inability to obtain appropriate clinical management. Section 9(2) recognises inability to obtain appropriate clinical management for dengue virus infection as an independent factor. Section 10(2) limits the application of that factor: it applies only to material contribution to, or aggravation of, dengue virus infection where the person’s dengue virus infection was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

Relationship to service and relevant service. The instrument requires that any factor in s 9 be related to the person’s relevant service (s 10(1)). “Relevant service” is defined in Schedule 1 and is limited to: (a) eligible war service under the VEA other than operational service; (b) defence service under the VEA other than hazardous service and British nuclear test defence service; and (c) peacetime service under the MRCA (Schedule 1). This is a narrower list than all possible service types under the principal Acts.

Death and terminal events. The instrument expressly covers death from dengue virus infection, defining such death to include deaths from terminal events or conditions contributed to by dengue virus infection (s 7(5)). “Terminal event” is defined in Schedule 1 to include pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function.

Interdependence with other Statements. Section 11 provides that if a factor in s 9 refers to an injury or disease covered by another Statement of Principles made under subsection 196B(3) of the VEA, then the factors in that other Statement apply according to its terms as in force from time to time. This creates a modular mechanism for cross‑referencing causation rules.

Basis and standard of proof. The instrument records that the Authority has taken “sound medical‑scientific evidence” into account and is of the view that it is “more probable than not” that dengue virus infection can be related to relevant service (s 8). The balance of probabilities standard is the threshold the instrument is addressing; the instrument itself is a determinative statement of causation factors rather than a statement prescribing the decision-maker’s final outcome.

Primary persons affected are claimants under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA) whose claims fall within the specific claim provisions cited (s 5). The instrument applies to "a claim to which section 120B of the VEA or section 339 of the MRCA applies" (s 5). The instrument therefore addresses veterans and Defence Force members seeking a finding that dengue virus infection or death from dengue virus infection is connected with their relevant service for the purposes of those statutory claim provisions. The instrument does not itself alter entitlement criteria in those Acts; it specifies the factors decision-makers are to apply when assessing whether the disease is connected to relevant service.

Who decides. The Repatriation Medical Authority is the author of the instrument and the body that determined the Statement (cover page and s 3). The instrument will be applied by decision-makers and claims administrators who adjudicate VEA and MRCA claims under the cited sections. The instrument itself does not set out the administrative process; it prescribes the causation factors to be used by decision-makers.

Who bears evidential burden. The instrument identifies the factors that “must exist” before a court or decision-maker can conclude, on the balance of probabilities, that dengue virus infection is connected to service (s 9). It follows that a claimant must adduce evidence establishing at least one of those factors and the link to relevant service (s 10). The Schedule 1 definitions shape what evidence is relevant: travel or location evidence of being in an area with dengue transmission, documentation of mosquito exposure incidents, records of blood transfusions or transplants, and records showing inability to obtain appropriate clinical management will be the central categories of proof the instrument authorises decision-makers to consider.

Service categories excluded or limited. The definition of relevant service in Schedule 1 excludes certain service categories by explicit language. Relevant service under the Statement is confined to eligible war service excluding operational service, defence service excluding hazardous service and British nuclear test defence service, and peacetime service under the MRCA. Persons whose service falls only within excluded categories will not be within the instrument’s scope. Decision-makers must therefore match the claimant’s service history against the instrument’s definition of relevant service to determine applicability.

Other affected parties. Medical practitioners and hospitals providing clinical records and diagnostic testing will be indirectly affected because their records are likely to be the core evidence used to establish a factor. Administrators in the Department of Veterans’ Affairs and case officers under the MRCA will be affected because they must apply the Statement when assessing causation for the enumerated claims. The Repatriation Medical Authority itself will be affected operationally because the Statement establishes the medical criteria it has endorsed for dengue-related causation decisions.

No litigated cases or statutory penalties in the instrument. The Statement does not itself create offences, penalties, or administrative sanctions; its effect is evidentiary and procedural in the processing of claims. Any costs of benefits that follow from an accepted claim will be borne under the VEA or MRCA claim frameworks and budgets, not by the Statement itself.

This instrument imposes no enforcement obligations, criminal penalties or new statutory duties on individuals. Instead it prescribes the conditions that must be satisfied, on the balance of probabilities, for decision-makers to find that dengue virus infection or death from it is connected with relevant service. That in turn affects rights to entitlements under the VEA or MRCA where those Acts provide benefits for service‑related injury or disease.

Claimant’s obligations and evidentiary rights. The Statement requires that at least one factor in section 9 exists and be related to the person’s relevant service (s 9, s 10(1)). Practically, this creates an evidentiary obligation for claimants to produce material that demonstrates either: (a) exposure to dengue virus within 14 days before clinical onset using the modes in the Schedule 1 definition of exposure, or (b) inability to obtain appropriate clinical management when the other limits in s 10(2) are satisfied. The Statement does not itself prescribe specific documentary formats, but it sets the contours of what evidence is relevant and therefore within the claimant’s procedural rights to present.

Decision‑maker duties. Decision-makers adjudicating claims under the referenced statutory provisions must apply this Statement when assessing causal connection for dengue virus infection and deaths attributed to it, because the instrument “applies to a claim to which section 120B of the VEA or section 339 of the MRCA applies” (s 5). The instrument places the Authority’s medical view on the record and requires that decision-makers assess the factual circumstances against the factors and definitions set out. Section 11 requires cross-application of other Statements where a factor refers to another injury or disease covered by a Statement, so decision-makers have a duty to consult and apply other relevant Statements as in force.

Limitations on the clinical‑management factor. The instrument limits the scope of s 9(2) by reference to s 10(2). The clinical‑management factor applies only to “material contribution to, or aggravation of” dengue virus infection where the infection was suffered or contracted before or during but did not arise out of the person’s relevant service. That is a legal constraint on how s 9(2) may be used to link disease to service, and decision-makers must treat that factor accordingly.

Rights related to death claims. The Statement expressly treats death from dengue virus infection as included where the death results from a terminal event or condition contributed to by dengue virus infection (s 7(5)). This gives rise to a right for a claimant or estate to seek a finding that death was related to service where evidence shows dengue contributed to a recognised terminal event as defined in the Schedule.

Authority’s evidential statement. Section 8 records the Authority’s view that, based on sound medical‑scientific evidence, it is more probable than not that dengue infection and death from it may be related to relevant service. This is not a statutory duty but functions as the Authority’s settled medical position to inform decision-makers and claimants about the standard of causation the Statement supports.

No express appeal or review route in the Statement. The instrument does not itself establish appeal rights, review mechanisms, or procedures. Those rights and procedures will be those provided under the VEA and MRCA claims frameworks. The Statement operates as an input into those decision processes rather than creating new procedural rights.

The Statement contains no provisions creating offences, civil penalties, or enforcement mechanisms. It is a non‑punitive, declaratory instrument that establishes medical and causal thresholds to be used in claims assessments under the VEA and MRCA (s 3, s 5). Enforcement in the sense of compliance is therefore indirect: the Statement is enforced through its application by decision-makers deciding entitlement under the statutory claim provisions it references.

Who enforces and how. The Repatriation Medical Authority is the making body of the instrument (s 3). Practical application and any consequent benefit payments, compensation, or administrative determinations will be carried out by the relevant statutory administrators under the VEA or MRCA. The Statement identifies the factors a decision-maker must consider when determining whether disease is connected with relevant service, so enforcement consists of administrative application in the adjudication of claims, not a separate enforcement regime embedded in the Statement.

Consequences of acceptance or rejection. If a decision-maker accepts that a claimant’s dengue infection or death from dengue infection is connected to relevant service, consequences flow from the VEA or MRCA statutory schemes (the Statement applies to claims under s 120B VEA and s 339 MRCA, s 5). The Statement itself does not specify the nature or quantum of benefits. Conversely, if a claimant cannot establish any of the factors in s 9 or cannot show that an established factor was related to relevant service (s 10(1)), the Statement provides the basis for a decision-maker to find no service connection. The Statement supplies the causal framework used in those determinations.

Burden of proof. The instrument frames the threshold as “on the balance of probabilities” (cover page title and s 8 language quoting “more probable than not”). That is the civil standard of proof that decision-makers will apply when using these factors. The Statement does not alter procedural allocation of burdens under the VEA or MRCA, but it expresses the Authority’s view on the evidentiary sufficiency required for causation.

No inspection or compliance powers. The Statement contains no administrative powers such as inspection, requirement to produce documents, or coercive evidence gathering. Any such powers would need to be sought under the general administrative provisions of the Department of Veterans’ Affairs or the MRCA framework.

Record‑keeping and evidentiary reliance. Because the Statement depends on factual predicates such as exposure within 14 days prior to onset and inability to obtain appropriate clinical management, enforcement via claims processes will rely heavily on medical records, travel and transfusion/transplant documentation, and other records. The Statement effectively requires decision-makers to assess the available evidence against its definitions; it does not prescribe how evidence must be obtained.

The Statement is an instrument made under subsection 196B(3) of the Veterans' Entitlements Act 1986 (s 3) and expressly applies to claims to which specific provisions of the VEA and MRCA apply (s 5). It therefore sits within the statutory machinery used to determine service connection for claims under those Acts. The Statement does not amend the VEA or MRCA; it provides the Repatriation Medical Authority’s determinative medical view on causation factors for dengue-related claims.

Relationship to the VEA and MRCA. Section 5 explicitly limits application to claims to which s 120B of the VEA or s 339 of the MRCA apply. The Statement must be read in conjunction with those statutory provisions, which set out the administrative and legal consequences of a finding that a disease is connected to service. The Statement provides the medical causation criteria that decision-makers should use when applying the relevant statutory tests contained in those Acts.

Interaction with other Statements of Principles. Section 11 creates an operational interaction with other Statements determined under subsection 196B(3) of the VEA. If a factor in section 9 refers to an injury or disease already covered by another Statement of Principles, the factors in that other Statement apply according to its terms as in force. This cross-reference means that where exposure or causation depends upon a distinct disease or injury, the relevant other Statement's rules will govern that element of the causation analysis.

Use of ICD‑10‑AM classification. Section 7(3)-(4) notes that dengue virus infection attracts ICD‑10‑AM codes A90 or A91 and cross-references the ICD‑10‑AM Tenth Edition. However, s 7(3) clarifies that, for the purposes of this Statement, the operative meaning of dengue virus infection is the definition in s 7(2) rather than being determined solely by the ICD code. Decision-makers may use ICD coding as supporting material but must apply the instrument’s definitional text.

No express conflict resolution clause. The Statement does not include a clause specifying how to resolve conflicts between it and other instruments or statutory provisions. The textual hierarchy is implicit: the Statement is made under the VEA and intended to be used in applying the VEA and MRCA provisions. Where other Statements apply by operation of s 11, their terms apply “as in force from time to time.”

Scope limits by reference to “relevant service.” The Schedule 1 definition of “relevant service” restricts which service categories trigger application of the Statement. That interacts with the VEA and MRCA definitions of service because a claimant might have multiple kinds of service; decision-makers must determine whether the claimant’s service falls within the Statement’s relevant-service definition before applying its factors.

Administrative processes and appeals under the VEA/MRCA. The Statement does not alter the statutory appeal or review processes that operate under the VEA and MRCA. Where a claim’s outcome depends on the application of this Statement, any review or appeal will proceed under the appeal mechanisms provided in those Acts rather than under a separate process created by the Statement.

This instrument, titled Statement of Principles concerning dengue virus infection (Balance of Probabilities) (No. 79 of 2020), was dated 30 October 2020 (cover page) and commences on 30 November 2020 (s 2). Section 4 expressly repeals the prior Statement of Principles concerning dengue fever No. 14 of 2012 (Federal Register of Legislation No. F2012L00444), which had been made under the same subsection 196B(3) of the VEA. The repeal is absolute as framed; the 2012 Statement is replaced by this instrument for the purposes of statements made under subsection 196B(3).

The instrument does not contain any amending or savings provisions beyond the express repeal. It does not record incremental amendments or a staged commencement; the single commencement date applies to the instrument as a whole.

No further amendment history is supplied in the text. The Statement’s s 11 mechanism contemplates that other Statements of Principles may be updated “as in force from time to time,” and therefore this instrument operates within a broader, potentially changing set of Statements. Any subsequent amendments to this instrument, or further repeals, would need to be made by the Repatriation Medical Authority under subsection 196B(3) of the VEA and would be reflected in the Federal Register of Legislation or other official publication.

Administrative record evidence. The cover page records the instrument’s execution under the Authority’s seal and includes the Chairperson’s name, Professor Nicholas Saunders AO, indicating formal adoption by the Authority. The instrument also records the statutory basis for its making (s 3). Those administrative entries supply the provenance and finality of the instrument as adopted on the dates shown.

No transitional provisions recorded. The instrument contains no clauses providing transitional arrangements for claims lodged before commencement. Because it repeals the earlier 2012 Statement, decision-makers must consider which Statement applies to a claim depending on the statutory framework and any commencement or retrospective rules under the VEA or MRCA. The Statement itself does not specify transitional application; that determination will be governed by the wider administrative and legal rules that apply to Statements of Principles and claims under the VEA and MRCA.

The instrument’s text contains no references to litigation, judicial decisions, or precedent cases. It does not record any court rulings interpreting this Statement, nor does it cite authority by way of case law. The Statement is an administrative medical determination prepared and issued by the Repatriation Medical Authority.

Because the Statement is dated and commenced in late 2020, any litigation testing the Statement’s application in individual claims would be found in administrative or judicial review decisions under the VEA and MRCA frameworks rather than in the Statement itself. Those decisions, if any, are not recorded in the instrument. Users seeking litigation history must consult the relevant administrative and judicial records external to this instrument, because the Statement does not include a litigation history section.

The instrument does, however, create the factual and legal predicates that could be points of dispute in future proceedings. Examples of potentially litigated issues include the proper interpretation and application of the 14‑day exposure window in s 9(1), the scope and evidentiary threshold for “inability to obtain appropriate clinical management” in s 9(2) and s 10(2), and the proper identification of whether a person’s service falls within the Statement’s Schedule 1 definition of relevant service. Any judicial or tribunal consideration of such questions would turn on factual matrixes and the administrative law standards applicable under the VEA and MRCA. The Statement itself does not provide guidance on how those procedural or legal challenges should be litigated.

No named cases. The instrument does not name or rely on any court decisions, nor does it purport to overrule or respond to any specific judgment. It is presented as a medical‑scientific determination made by the Authority under its statutory function.

Narrow temporal requirement. Section 9(1) requires exposure to dengue virus within 14 days before the clinical onset of dengue virus infection. That window is explicit and potentially dispositive. Claimants whose documented exposure predates the 14‑day window will be unable to establish s 9(1) unless they can adduce evidence fitting another mode of exposure set out in the Schedule or rely on s 9(2) where applicable. The Statement does not define “clinical onset” beyond the general disease notes in s 7(2), so timing disputes about first symptom recognition or recorded onset dates may be litigated or contested.

Scope of “inability to obtain appropriate clinical management.” Section 9(2) is an independent factor, but s 10(2) restricts its use to material contribution or aggravation where the infection was suffered or contracted before or during but did not arise out of the person’s relevant service. That means the clinical‑management factor does not apply to infections that arose out of relevant service; it is a narrow remedial trigger for cases where pre‑existing disease was made worse by inadequate clinical care encountered in the context of service. Determining whether the infection “did not arise out of” service and whether failure to obtain appropriate clinical management materially contributed or aggravated the condition are fact‑specific inquiries that may be contentious.

Definition of relevant service excludes certain categories. Schedule 1 defines “relevant service” narrowly. Eligible war service except operational service, defence service except hazardous service and British nuclear test defence service, and peacetime service under the MRCA are included. Service characterised as “operational service,” “hazardous service,” or “British nuclear test defence service” is excluded by the wording. Claimants and decision-makers must take care to classify service accurately against this instrument’s definition; misclassification will determine whether the Statement applies to a given claim.

Interaction with other Statements may extend or restrict application. Section 11 imports factors from other Statements where a factor refers to an injury or disease covered by another Statement. That creates an interdependency that may complicate claim preparation where a factor involves a comorbid disease or another causal mechanism. Claimants should identify any cross-referenced Statements early because those Statements may impose different thresholds or definitions.

ICD‑10‑AM reference is subordinate to the instrument’s definition. Although s 7(3) notes that dengue attracts ICD‑10‑AM codes A90 or A91, s 7(3)-(4) says the meaning for the Statement is that given in s 7(2). Decision-makers should not treat an ICD code alone as determinative; the instrument’s textual definition governs.

Death and terminal events. Death from dengue virus infection is included only where the death is from a terminal event or condition contributed to by dengue virus infection (s 7(5)). The Schedule defines terminal events narrowly to include specific causes such as pneumonia and respiratory failure. Establishing causation for death claims may require medical evidence linking dengue infection to one of the defined terminal events.

No procedural detail or evidentiary rules. The Statement does not set out evidentiary standards, document types, or thresholds for lab confirmation. It supplies the categories of facts decision-makers are to find, not the procedural steps for doing so. This absence places operational burdens on case officers and claimants to establish what documents will be acceptable in each context.

No transitional rules. The instrument repeals the 2012 Statement but contains no transitional provisions. For claims straddling the change of instrument, decision-makers and claimants must be attentive to which Statement applies, and the instrument gives no guidance about claims lodged before but decided after commencement.

Potential for factual disputes about exposure modes. The Schedule includes non‑mosquito exposure routes, including infected transfusions or percutaneous blood exposure. Proving such exposures will often depend on records of transfusions, transplants, or occupational exposures. The practical difficulty of proving such events may lead to contested decisions.

For claimants and advisers preparing a claim that dengue virus infection or death from dengue virus infection is connected with relevant service under the provisions cited, the Statement focuses evidence-gathering on the specific factors and definitions it sets out. The steps below derive from the instrument’s operative text and definitions.

1. Establish the form of relevant service. First determine whether the claimant’s service falls within the Schedule 1 definition of “relevant service.” The Statement applies only where service is eligible war service other than operational service, defence service other than hazardous service and British nuclear test defence service, or peacetime service under the MRCA (Schedule 1). Assemble service records, service history, and applicable personnel documentation to show the nature and dates of service.

2. Identify which factor under s 9 is being relied upon. The claimant must establish at least one of the two factors in s 9:

   • s 9(1): exposure to dengue virus within 14 days before clinical onset; or
   • s 9(2): inability to obtain appropriate clinical management, subject to the limits in s 10(2).

3. For s 9(1) claims assemble exposure evidence. The Schedule defines permissible exposures as mosquito bite by an infected mosquito, presence in a place with dengue transmission, percutaneous or mucocutaneous exposure to infected blood, or receiving infected blood products, stem cell or organ transplants. Relevant evidence can include:

   • travel or deployment records showing presence in a dengue transmission area and dates to establish the 14‑day pre‑onset window;
   • contemporaneous medical notes or patient histories recording mosquito bites or suspected bites;
   • laboratory confirmation of dengue infection (serology, PCR) and documented clinical onset dates; and
   • transfusion, transplant or occupational exposure records where non-mosquito exposure is alleged.

4. For s 9(2) claims assemble clinical‑management evidence and meet the s 10(2) constraint. If relying on inability to obtain appropriate clinical management, the claimant must also show that the person’s dengue infection was suffered or contracted before or during but did not arise out of relevant service (s 10(2)). Evidence should address:

   • timing showing disease was contracted before or during service and did not arise out of service;
   • contemporaneous attempts to access clinical care, including records of refusals, absence of facilities, or delayed care attributable to the service context;
   • medical records showing that lack of appropriate management materially contributed to or aggravated the dengue infection; and
   • expert medical opinion linking inadequate management to material contribution or aggravation.

5. For death claims, establish contribution to a terminal event. The Statement includes death where a terminal event or condition defined in the Schedule (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) was contributed to by dengue infection (s 7(5)). Evidence should include:

   • medical and hospital records showing the proximate cause of death and any linkage to dengue infection;
   • post‑mortem reports or treating clinician opinions connecting dengue infection to the terminal event; and
   • timelines showing infection and subsequent terminal condition progression.

6. Anticipate and address timing disputes. Because s 9(1) specifies a 14‑day pre‑onset exposure window, carefully document the first recorded clinical signs and the dates of any exposure events. If onset timing is uncertain, obtain medical records or clinician statements clarifying when symptoms began.

7. Consider intersections with other Statements. If any factor refers to another injury or disease that has its own Statement of Principles, identify and assemble evidence required by that other Statement, because s 11 imports those factors “as in force from time to time.” Cross-referenced Statements may demand additional evidence or different causal standards.

8. Produce clear medical evidence linking exposure, disease and service. The Statement is framed as a medical causation instrument. Technical medical documentation,lab confirmations, treating physician statements, diagnostic imaging and pathology reports,will be central. Where clinical management issues are relied upon, obtain contemporaneous clinical records and expert opinions on standards of care and causation.

9. Prepare to show the relationship of the factor to relevant service. Section 10(1) requires that any factor in s 9 must be related to the person’s relevant service. Demonstrate how the exposure or inability to obtain care occurred in the course of or because of the circumstances of service evidenced in personnel or deployment records.

10. Keep track of the Statements in force. Because the instrument and other Statements may be updated “as in force from time to time” (s 11), ensure the relevant versions of any other Statements are cited in the claim and that the Authority’s current Statement is the operative 2020 instrument rather than the repealed 2012 Statement (s 4).

Operational advice for administrators and case officers. When the Statement is used in adjudication:

• Verify the claimant’s service category against the instrument’s “relevant service” definition before applying the s 9 factors.
• Treat the 14‑day requirement in s 9(1) as a strict temporal element that must be satisfied by evidence of exposure and documented onset.
• For s 9(2) matters, request specific evidence about attempts to obtain appropriate clinical management and expert opinion on whether the absence of that care materially contributed to or aggravated the condition, and confirm the infection’s timing relative to service so s 10(2) constraints are met.
• Where cross-referenced Statements apply under s 11, pull those Statements into the file and ensure their factors are used as prescribed.

Record-keeping and evidence preservation. Given the Statement’s reliance on documentary and medical evidence, parties should preserve medical records, deployment logs, transfusion/transplant documentation, travel evidence, and contemporaneous notes. Expert medical reports explaining causation in terms tied to the Statement’s definitions will be valuable.

Limitations and practical risk mitigation. Because the Statement does not prescribe procedural or evidentiary rules, practitioners should proactively obtain robust documentation rather than relying on general assertions of exposure or inadequate care. Expert medical opinion that directly addresses the Statement’s factors and ties them to the claimant’s service history will reduce the risk of a negative outcome.

In sum, compliance consists of producing evidence that fits the Statement’s textual definitions and temporal constraints and establishing the required link between an identified factor and the claimant’s relevant service.